

1 **Economic burden and health-related quality-of-life among infants**
2 **with respiratory syncytial virus infection: a multi-country prospective**
3 **cohort study in Europe**

4 Running head: Cost and quality of life of RSV infants

5 Zhuxin Mao^{1*}, Xiao Li¹, Ana Dacosta-Urbiet^{2,3,4}, Marie-Noëlle Billard⁵, Joanne Wildenbeest⁵,
6 Koos Korsten^{6,7}, Federico Martín-Torres^{2,3,4}, Terho Heikkinen⁸, Steve Cunningham⁹,
7 Matthew D Snape¹⁰, Hannah Robinson¹⁰, Andrew J Pollard¹⁰, Maarten Postma^{11,12,13}, Benoit
8 Dervaux¹⁴, Niel Hens^{15,1}, Louis Bont^{6,16}, Joke Bilcke¹ and Philippe Beutels¹ for RESCEU
9 investigators.

- 10 1. Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID),
11 University of Antwerp, Belgium
12 2. Translational Paediatrics and Infectious Diseases, Paediatrics Department, Hospital Clínico
13 Universitario de Santiago de Compostela, Santiago de Compostela, Spain
14 3. Genetics Vaccines Infectious Diseases and Pediatrics research group GENVIP, Instituto de
15 Investigación Sanitaria de Santiago (IDIS)
16 4. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES),
17 Instituto de Salud Carlos III, Madrid, Spain
18 5. Department of Paediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital,
19 University Medical Center Utrecht, Utrecht, the Netherlands
20 6. Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht,
21 Utrecht, Netherlands
22 7. Amsterdam UMC location University of Amsterdam, Department of Medical Microbiology,
23 Meibergdreef 9, Amsterdam, The Netherlands
24 8. Department of Pediatrics, University of Turku and Turku University Hospital, Turku, Finland
25 9. Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom
26 10. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford
27 Biomedical Research Centre, Oxford, United Kingdom
28 11. Department of Health Sciences, University Medical Centre Groningen, University of Groningen,
29 Groningen, The Netherlands
30 12. Department of Economics, Econometrics and Finance, Faculty of Economics and Business,
31 University of Groningen, Groningen, The Netherlands

- 1 13. Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Padjadjaran
2 University, Bandung, Indonesia
3 14. Institut Pasteur U1167 – RID-AGE – Facteurs de risque et déterminants moléculaires des
4 maladies liées au vieillissement, Univ Lille, Inserm, CHU Lille, 59000, Lille, France
5 15. Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BIOSTAT), Data
6 Science Institute (DSI), Hasselt University, Hasselt, Belgium
7 16. The Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands
8

9 *Corresponding author: Zhuxin Mao

10 Email: Zhuxin.Mao@uantwerpen.be

11 Tel: +32 484781482

12 Postal Address: Campus Drie Eiken, room D.S.242, Universiteitsplein 1, Wilrijk, Belgium,
13 2610

14

1 **Abstract**

2 Background

3 Respiratory syncytial virus (RSV) causes a considerable disease burden in young
4 children globally, but reliable estimates of RSV-related costs and health-related quality-
5 of-life (HRQoL) are scarce. This study aimed to evaluate the RSV-associated costs and
6 HRQoL effects in infants and their caregivers in four European countries.

7 Methods

8 Healthy term-born infants were recruited at birth and actively followed up in four
9 European countries. Symptomatic infants were systematically tested for RSV.
10 Caregivers recorded the daily HRQoL of their child and themselves, measured by a
11 modified EQ-5D with Visual Analogue Scale, for 14 consecutive days or until
12 symptoms resolved. At the end of each RSV episode, caregivers reported healthcare
13 resource use and work absenteeism. Direct medical costs per RSV episode were
14 estimated from a healthcare payer's perspective and indirect costs were estimated from
15 a societal perspective. Means and 95% confidence intervals (CI) of direct medical costs,
16 total costs (direct costs + productivity loss) and quality-adjusted life-day (QALD) loss
17 per RSV episode were estimated per RSV episode, as well as per subgroup (medical
18 attendance, country).

19 Results

20 Our cohort of 1041 infants experienced 265 RSV episodes with a mean symptom
21 duration of 12.5 days. The mean (95% CI) cost per RSV episode was €399.5 (242.3,

1 584.2) and €494.3 (317.7, 696.1) from the healthcare payer's and societal perspective,
2 respectively. The mean QALD loss per RSV episode of 1.9 (1.7, 2.1) was independent
3 of medical attendance (in contrast to costs, which also differed by country). Caregiver
4 and infant HRQoL evolved similarly.

5 Conclusion

6 This study fills essential gaps for future economic evaluations by prospectively
7 estimating direct and indirect costs and HRQoL effects on healthy term infants and
8 caregivers separately, for both medically attended (MA) and non-MA laboratory-
9 confirmed RSV episodes. We generally observed greater HRQoL losses than in
10 previous studies which used non-community and/or non-prospective designs.

11 Key words

12 RSV; cost; productivity loss; health-related quality-of-life; quality-adjusted life-years;
13 infants; outpatients; prospective study; Europe

14

1 **Background**

2 Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract
3 infection (ALRI) among young children. Li et al. estimated globally 33 million RSV-
4 associated ALRI episodes, 3.6 million hospital admissions and 26,300 in-hospital
5 deaths in children below 5 years of age in 2019, with nearly 40% of hospital admissions
6 in infants younger than 6 months [1]. In Europe, RSV infections were found to generate
7 a high disease burden in young children in the community [2, 3].

8 Substantial efforts have been made to develop preventive measures for RSV illnesses.

9 Several RSV immunisation candidates are currently in late-stage clinical trials and
10 some have shown their efficacy to protect young infants against RSV infection [4, 5].

11 It is therefore expected that various prophylactic intervention strategies against RSV
12 will become available soon upon successful regulatory authorisation. Subsequently,
13 evaluating the cost-effectiveness of potential infant interventions against RSV is
14 essential for policymakers to optimise their decisions to design immunisation programs
15 in the near future. To inform such an evaluation, reliable estimates of cost and health-
16 related quality-of-life (HRQoL) associated with RSV infection in infants are crucial.

17 A recent systematic review summarized RSV-associated costs in children younger than
18 five years and found limited published RSV ambulatory cost data for regions outside
19 North America [6]. We found three European studies reporting RSV-associated direct
20 medical cost per RSV outpatient episode, but one only recruited children in emergency
21 departments [7], and one only included pre-term infants [8]. The only community-based

1 study was not able to identify a sufficient number of non-medically attended RSV
2 infants to calculate the cost burden of this group [9].

3 The estimates of RSV-related HRQoL loss among infants are also scarce. Previous cost-
4 effectiveness studies of potential infant RSV vaccination were not able to refer to
5 quality-adjusted life years (QALYs) loss estimated specifically for RSV infant episodes
6 [10-12]. Recently, two studies investigated HRQoL loss due to RSV infection in
7 children younger than 5 years old, but both estimates were calculated based on
8 medically attended patients only [13, 14]. The health utility of children with RSV not
9 seeking medical care has no current evidence available, which is a notable research gap.

10 The primary aim of this study was to estimate the RSV-associated costs and HRQoL
11 effects among infants and their caregivers during an RSV episode with and without
12 seeking professional medical care, using data from a prospective European cohort study.

13 The ultimate aim is to support future cost-effectiveness analyses for emerging RSV
14 immunisation programs.

15 **Methods**

16 This prospective observational multi-country cohort study recruited healthy term-born
17 infants in four European countries (UK, Spain, Finland and the Netherlands) between
18 July 2017 and November 2019 which were actively followed until their first birthday
19 during the RSV seasons of 2017-18, 2018-19 and 2019-20 [15]. A sample size of 1000
20 infants was estimated for this cohort, which would produce a two-sided 95% Clopper-

1 Pearson CI with a half-width of 2%, for an assumed incidence of medically attended
2 ARI of 10%, accounting for 10% loss to follow-up [16]. Infants were recruited at birth
3 and a background questionnaire was completed at intake by caregivers (mother, father
4 or other) to record infants' and caregivers' background characteristics (including socio-
5 demographics and potential risk factors). During the RSV season in the first year of life,
6 parents were contacted weekly and if the child had respiratory symptoms, a nasal
7 sample was taken during a home visit and the sample was analysed for RSV (for more
8 details see [15]).

9 Caregivers were provided with a diary in the local language of the country, to record
10 the daily symptoms for 14 consecutive days. This enabled us to obtain the mean length
11 of symptom duration per RSV episode. They were also asked to record HRQoL of their
12 children as well as their own HRQoL from symptom onset for 14 days or until
13 symptom-free (see below). After completing the 14-day diary, caregivers were also
14 asked to record healthcare resource use and work absenteeism 14 days after the onset
15 of each symptomatic period (hereafter termed "the end-of-diary"). Additionally, all
16 caregivers were followed up to complete a questionnaire about their own HRQoL when
17 their child reached approximately one year of age. Follow up is continuing until 3 years
18 of age but falls beyond the scope of the current paper.

19 **Cost**

20 Number of days off from work and healthcare resource use, including consultations of
21 general practitioners (GPs), out-of-hours services, emergency departments and

specialists as well as medication use were extracted from the end-of-diary record. Hospital admission and duration were obtained from patients' hospitalisation records. Country-specific national unit costs for healthcare visits, hospitalisation and medication were obtained from corresponding databases: NHS reference cost (UK) [17], 'Kostenhandleiding' (the Netherlands) [18], 'Terveystien ja sosiaalihuollon yksikkökustannukset Suomessa vuonna 2017' (Finland) [19] and 'Diario Oficial de Galicia' (Spain) [20]. Productivity loss per day was estimated following the human capital approach, using the gross average work-day salary, based on the number of days off work reported by caregivers. Costs were inflated and converted to Euro (€) year 2021. See Supplementary Methods (S. Method 1, S. Method 2, and Table S.1) for more details.

Direct costs per episode were calculated by multiplying the quantity of healthcare resource use with the corresponding unit cost. Indirect costs per episode were obtained by multiplying off-work days with the average gross salary per day (Table S.1).

We calculated costs from (1) a healthcare payer's perspective (i.e., direct cost per RSV episode) and (2) a societal perspective (i.e., total cost per RSV episode = direct cost + indirect cost).

HRQoL

Caregivers (one caregiver in each household) were asked to rate their and their children's HRQoL during the RSV episode based on the EQ-5D instrument. Each day, caregivers were asked to answer the "Usual Activities" (UA) and "Anxiety/Depression"

1 (AD) dimensions from the EQ-5D-5L [21] and the EQ-5D-VAS (visual analogue scale)
 2 for themselves, and to complete the “Pain/Discomfort” and “Sad” dimension from EQ-
 3 5D-3L-Y [21] and the EQ-5D-VAS for their infants. An additional question, phrased
 4 and structured in the same manner as the 5-dimension questions on the EQ-5D-5L was
 5 presented immediately after the caregivers’ own VAS evaluation. This question is
 6 referred to as “worried about my child” (See S. Method 3). These five questions to
 7 determine HRQoL were selected based on available literature and extensive
 8 deliberation between senior health economists and clinicians, adapted according to the
 9 designs and aims of this prospective cohort study (further addressed in the Discussion).
 10 Because not all dimensions of the EQ-5D were measured, instead of calculating health
 11 utility scores, we calculated the differences in disutility of the two available health
 12 dimensions between baseline and on each diary day and assumed the other three health
 13 dimensions did not change due to RSV infection. For example, if a caregiver had no
 14 problem [level 1] in UA and AD at baseline and reported level 3 problems in these two
 15 dimensions on diary Day 1, the utility loss on Day 1 would be: $(1 - UA_3 - AD_3) - (1 - UA_1 - AD_1) = UA_1 - UA_3 + AD_1 - AD_3$. UA_n and AD_n are the coefficients in EQ-5D’s valuation
 16 regression models for calculating the utility values, representing the estimated disutility
 17 of having problems on dimension UA or AD at level n. The utility loss can be
 18 understood as quality-adjusted life-day (QALD) loss in this study. We obtained the total
 19 QALD loss for each episode. We used caregivers’ HRQoL collected around the infants’
 20 first birthday as the baseline HRQoL for caregivers. Caregivers’ HRQoL on Day 14 or
 21

1 at birth was not used as baseline, because more than half of the episodes still reported
2 symptoms on Day 14 and caregivers reported poorer HRQoL at birth than during the
3 RSV symptom period. Because no HRQoL was collected for infants at age one year
4 and there are no population norms for infants of this age in most countries, we assumed
5 their baseline HRQoL to be in full health (no problem in Sad and Pain dimension). For
6 caregivers' QALD loss, the corresponding country's EQ-5D-5L valuation models were
7 used [22-24]. Since only Finland does not have an EQ-5D-5L valuation model, we used
8 the only available Nordic European country's valuation model (Denmark) for that
9 country [25]. For infant QALD loss, the only published Western European EQ-5D-Y
10 valuation model was used, which was for Spain [26].

11 **Summary statistics**

12 We calculated summary statistics for RSV-related direct and total costs. For HRQoL,
13 we calculated the percentage of respondents reporting problems on each available EQ-
14 5D dimension. In addition, summary statistics of VAS scores on each day as well as
15 that of total EQ-5D QALD loss for caregivers and infants during an RSV episode were
16 obtained. Because we did not observe a relationship between respondent's missing data
17 and the episode's characteristics, including age, gender and types of healthcare resource
18 use, we assumed our missing data were missing completely at random (assuming that
19 the missing data followed the same patterns as the non-missing data) and only included
20 those records without missing values to calculate the mean symptom duration and
21 QALD loss (see S. Result 3 and Table S.9). We did not account formally for right-

1 censored data (i.e. infants showing symptoms at Day 14), because QALD loss for Day
2 14 was negligible (see results). Costs, VAS scores, and QALD loss were also evaluated
3 in subgroups, stratified by type of healthcare resource use (no professional medical care
4 [non-MA], ambulatory care [AMB] or hospitalisation). We also calculated 95%
5 confidence intervals (95% CI) of the mean length of symptom duration, mean QALD
6 loss and mean costs using bootstrap (number of samples =1000). Different caregivers,
7 including mother, father, and other family members, may have completed the diary to
8 assess their infant's HRQoL during the RSV episode. Mean QALD loss was obtained
9 separately for RSV episodes for which HRQoL questions were answered only by the
10 father, and for episodes for which HRQoL questions were answered only by the mother
11 of the child with RSV.
12 All analyses were conducted in R (version 3.6.2) [27].

13 **Results**

14 We recruited 1041 infants at birth and identified 265 RSV episodes in 252 children in
15 total (Figure 1). No RSV-related deaths occurred. Nine episodes did not have healthcare
16 resource use data and 34 episodes did not have a returned symptom and HRQoL diary
17 record. Among those who had diary data, 184 episodes had a full 14-day diary record
18 of their symptom status. The RSV episodes' baseline characteristics are reported in
19 Table 1.

1 **Costs**

2 As shown in Table 2, the mean (95% CI) direct cost per RSV episode was €399.5 (242.3,
3 584.2) from a healthcare payer's perspective and the mean total cost was €494.3 (317.7,
4 696.1) from a societal perspective.

5 Eighteen RSV episodes required hospitalisation with a mean direct cost of €4587.9
6 (3085, 6229) per episode (healthcare payer's perspective). Hospitalised cases reported
7 a mean total cost of €5094.9 (3507, 6894) per admission from the societal perspective.

8 AMB patients (n=116) reported a mean direct cost of €167.8 (129.9, 202.9) per episode.

9 The incurred productivity loss was lower for AMB than for hospitalised RSV cases,
10 resulting in a mean total cost of €254.7 (197.9, 318.2) per AMB episode from the
11 societal perspective. Non-MA episodes (n=120) reported a mean direct cost of €1.8 (1.4,
12 2.3) (medication cost) with less than half of the non-MA episodes (47.5%) reporting
13 medication use. Patients not seeking professional medical care reported a mean total
14 cost of €44.2 (17.1, 81) from a societal perspective. We further categorised the AMB
15 patients into those who only received primary care, who only received secondary care
16 and who received both primary and secondary care. The estimates for these subgroups
17 can be found in Table S.5.

18 Mean costs varied across the four different countries (see Figure S.1 and Figure S.2).
19 Spanish RSV episodes yielded the highest mean costs from both perspectives, while
20 RSV episodes in the UK yielded the lowest mean costs. The cross-country discrepancy
21 was mostly due to different unit costs and different proportions of RSV episodes

1 requiring hospital and non-hospital medical attendance (Table S.2, Table S.3 and Table
2 S.4). For further cross-country comparisons, we obtained mean costs based on the
3 purchasing power parity and the results are available in Table S.6.

4 **HRQoL**

5 In total, 231 episodes of patients returned HRQoL data for at least one day and were
6 included in the HRQoL analysis. Figure 2 shows a peak in percentage of patients and
7 caregivers reporting any health problems around Days 3 and 4 after symptom onset
8 (percentages in Table S.7). The percentage of children reporting “pain” and “sadness”
9 were largely similar to the percentage of caregivers reporting “worry about my child”
10 (Figure 2). Any “sadness”, “pain” and “worry” were more frequently reported than
11 problems with “usual activities” and “anxiety/depression”. For instance, at Day 4 about
12 65-70% of the respondents reported any “sadness”, “pain” and “worry”, whereas 42%
13 of respondents reported problems with “usual activities” and 27% reported any
14 “anxiety/depression” (Figure 2).

15 Figure 3 shows that VAS for infants during an RSV episode showed a similar trend as
16 the EQ-5D dimensions, with the lowest VAS score (95% CI) on Day 4 [65.2 (62.8,
17 67.5)]. The VAS scores of caregivers exhibited a similar but lagged and less pronounced
18 trend. They dropped from 83.9 (82.1, 85.6) to 80.1 (78, 82.2) on Day 5, then went up
19 to 84.4 (82.1, 86.5) on Day 14. Hospitalised patients reported lower VAS scores than
20 those who received ambulatory care, whereas AMB patients had poorer VAS scores on
21 most symptom days compared to those who did not seek professional medical care. In

1 contrast, differences in VAS scores of caregivers caring for a hospitalised, AMB or non-
2 MA child with RSV were less noticeable. The boxplots for subgroup results by
3 healthcare resource use can be found in Figure S.3 and Figure S.4.

4 For 184 RSV episodes, the occurrence of symptoms (yes/no) was reported on each day
5 for 14 consecutive days. Types of recorded symptoms included cough, nasal congestion,
6 wheeze, shortness of breath and apnea. The lowest QALD losses were found for
7 patients with only cough and runny nose and the largest for patients with shortness of
8 breath (for further details see Table S.8). Among the RSV episodes, 22 episodes had
9 fluctuating symptoms, i.e., symptoms stopped then recurred with a mean length (95%
10 CI) of symptom duration (between the first and last symptom day) of 12.5 (11.6, 13.1)
11 days. Episodes without fluctuation in symptom reporting had the same mean length of
12 12.5 (12.1, 12.9) days. Non-MA patients (n=77) had a mean length of 12.4 (11.8, 12.9)
13 symptom days; AMB patients (n=77) reported a mean of 12.6 (12.1, 13.0) symptom
14 days; hospitalised patients (n=6) had the longest mean symptom duration of 13.3 (12.0,
15 14.0) days. Two episodes did not have healthcare resource use status: they had
16 symptoms for 10 days and for 14 days, respectively.

17 Table 3 shows the QALD loss of infants and caregivers per RSV episode. One hundred
18 and eighty episodes (78%) had full EQ-5D health information for infants and the mean
19 (95% CI) total QALD loss for each infant with RSV infection was 1.9 (1.7, 2.1). It is
20 worth noting that 106 episodes still reported symptoms on Day 14, although 73% of

1 these reported no QALD loss. As for caregivers, 164 of them (71%) reported full health
2 information and the total QALD loss was 0.1 (0, 0.2) per RSV episode.
3 Mean QALD loss was observed to be higher for AMB patients and their caregivers
4 compared to non-MA patients and their caregivers (see Table 3). Hospitalised episodes
5 yielded the most QALD loss. We observed that the largest and smallest QALD losses
6 were reported for Spain and the Netherlands, respectively. We also found mother
7 (caregiver) respondents (n=146) to report smaller QALD losses compared to father
8 respondents (n=8) for their infants.

9 **Discussion**

10 Our study is the first prospective multi-country study that measured costs and HRQoL
11 of RSV in healthy term babies and their caregivers during the first RSV season in a
12 community setting. We found a mean cost of €4587.9 (95%CI: 3085, 6229) per
13 hospitalised RSV episode from a healthcare payer perspective, which was more than
14 20-fold higher than the cost of AMB patients; the direct medical cost per non-MA RSV
15 episodes can be argued to be negligible. The mean QALD loss for an AMB RSV
16 episode was 2.3 (2.6, 2.0), which was almost twice as much as that of a non-MA episode.
17 This study observed a mean symptom duration of 12.5 (11.6, 13.1) days for RSV in
18 children under one year of age. This was twice as long as the previous study by Hodgson
19 and colleagues who reported a median of five symptom days in children under five
20 years, but they only focused on the coughing symptom and they obtained a poor
21 response rate for reporting the duration of symptoms (the response rate of their

1 questionnaires was 16%; the response rate of the symptom duration question was 67%)
 2 [14]. Our results are supported by two recent studies in Finland, which reported a mean
 3 duration of RSV illness to be 12 days (standard deviation [SD], 5.7) in infants under 1
 4 year of age [3] and a mean duration of 13 days (SD, 7.8) in children under 3 years [28] .
 5 One recent study reported the median direct cost per Spanish RSV infant patient (both
 6 inpatients and outpatients) to be €598.8 (IQR: 359.6–2425.9), which was higher than
 7 the median costs of the Spanish episodes in our study [the median cost of all Spanish
 8 episodes: €75.1 (IQR: 1.8-466.3); of MA episodes: €458.2 (139.3-639.1)] [13]. This
 9 may be because Díez-Gandía’s study recruited a higher proportion of hospitalised cases
 10 (40%) and the unit cost for inpatient service was considerably higher than that of
 11 outpatient service. In addition, their study included premature infants or infants with
 12 comorbidities, which can be risk factors for higher RSV-associated costs [6].
 13 We estimated the mean direct medical cost to be €167.8 (95%CI: 129.9, 202.9) per RSV
 14 ambulatory episode, which is slightly lower than what was estimated for two included
 15 European studies (one in Germany, i.e. €200 [9] and the other in Spain, i.e. €292 [7]),
 16 which were included in Zhang et al’s systematic review and meta-analysis [6]. This is
 17 likely due to differences in healthcare systems and associated costs. Differences in
 18 between-country costs per case in our study were mostly driven by different unit costs
 19 and different proportions of RSV episodes seeking medical attendance. Clearly, more
 20 country- or region-specific estimates of costs are most appropriate to inform future
 21 country- or region-specific economic evaluations.

1 This is the first multi-country study measuring indirect costs due to RSV in a
2 community setting in Europe. Our study assessed indirect costs representing
3 productivity loss associated with RSV infection to be approximately 20% of the societal
4 costs per episode. This ratio is comparable to previous studies which reported
5 productivity loss to be 5.8%–31.6% of the total cost [6].

6 Since no other study reported HRQoL impact on caregivers in the context of RSV, we
7 can only make limited comparisons with previous studies. The negative signs of QALD
8 loss in non-MA caregivers and in Finnish caregivers indicate that the average health
9 utility of these caregivers was reported to be slightly higher during the RSV episode as
10 compared to their average health utility around the infants' first birthday, but note that
11 the QALD gain is very small. Although not common, a few studies also reported that
12 caregivers received a positive benefit during the illness of their ill family member,
13 which may be due to feelings of altruism and fulfillment of obligations [29]. For non-
14 MA caregivers in our study, parents may need to go to work again at the infants' first
15 birthday, which can cause more negative impacts than when their child suffered from
16 (mild) RSV during their parental leave. As for Finland, Finnish parents have the longest
17 government-mandated parental paid leave [30], and it was found that mothers' better
18 mental health was generally associated with more generous parental leave policies [31].
19 We reported a larger mean QALY loss per RSV episode under age of one year (MA:
20 $2.4/365 \text{ days} = 6.58 \times 10^{-3}$; non-MA: 3.62×10^{-3}) compared to Hodgson's study for
21 children under age of five years [14]: (MA: 3.823×10^{-3} , non-MA: 3.024×10^{-3}). We

1 note the following differences between our studies. First, the QALY loss estimate by
2 Hodgson et al was predicted using the EQ-5D of suspected RSV among children who
3 experienced RSV-like symptoms, while we directly assessed health status information
4 of confirmed RSV in children under one year old. RSV-confirmed cases may
5 experience larger health decline than the suspected cases and the choice of respondents
6 can affect the valuation of health states [32]. As was found in our study, even the gender
7 of the caregivers (mother vs father) can influence the interpretation and scoring of
8 HRQoL for caregivers themselves and their children. Second, QALY loss in the
9 Hodgson study was calculated based on a shorter symptom duration (median 5 days)
10 than the reported symptom duration in our study. Third, Hodgson and colleagues used
11 the full EQ-5D health profile, and the UK value set of EQ-5D-3L to calculate QALY
12 for very young children but questions such as “mobility”, “looking after myself” and
13 “usual activities” were less appropriate for use in valuing the health of an infant less
14 than one year. Fourth, we assumed the baseline HRQoL of infants to be in full health
15 which can overestimate QALY loss. Lastly, because RSV disease severity is higher in
16 infants under one year old and decreases with age [1], QALY loss can be greater for
17 children younger than one than those under five years. Diez-Gandia and colleagues [13]
18 calculated the HRQoL loss to be 37.5% and 31.5% on days 0 and 7 since the diagnosis
19 of the disease, respectively, which was comparable to our results. We observed a mean
20 HRQoL loss of 29% and 46% for AMB and hospitalised infant patients on the worst
21 day, respectively. The slight discrepancy may be due to the different questionnaires

1 used and because Diez-Gandia and colleagues did not differentiate between caregivers
2 and children for calculating HRQoL loss (they combined children's symptoms,
3 children's behaviours, parents' concerns, parents' emotions and the impact of the
4 infection on family activities). Another study [33] estimated the disutility of children
5 due to RSV infection to be between 0.14 and 0.57, which was comparable to our results
6 (the mean utility loss per day for infants was between 7% to 23%), but their estimate
7 was obtained from a proxy perspective: participants imagined hypothetical scenarios in
8 a time trade-off experiment to give their preferences.

9 Despite not being an aim of this study, it was found that the evolution of the VAS scores
10 of caregivers seemed to be driven by the persistence of a lower VAS score in the infant.
11 This is consistent with previous studies showing evident correlation between children's
12 and caregivers' HRQoL, especially in children and caregivers affected by acute
13 illnesses [34, 35].

14 ***Strengths and Limitations***

15 One strength of this prospective cohort study is that it actively followed healthy infants
16 and identified those with RSV infection in a community setting. While previous studies
17 were mainly conducted in an inpatient setting and did not have detailed costs and
18 HRQoL data for RSV infant patients, especially for those who did not seek medical
19 care, we were able to fill this research gap. We confirmed that costs of non-MA patients
20 seem negligible compared to costs of patients seeking professional medical care, but
21 the HRQoL loss of non-MA seems not negligible.

1 We aimed to reflect the reality of the cost and health burden of RSV by obtaining the
2 quantities of healthcare resource use, productivity loss as well as detailed changes of
3 HRQoL directly from patients and their caregivers that were experiencing RSV
4 infection. We collected daily health data to ensure HRQoL changes were monitored
5 throughout the whole RSV infection period and were with minimal recall biases,
6 compared to the previous studies that only obtained one (worst health) [14] or two time
7 points (on day 7 and day 14 after symptom onset) during an RSV episode [13].

8 Our study has the following limitations. First, in this descriptive paper, we opted to
9 apply a practical, conservative but less efficient approach to deal with missing data. To
10 the best of our knowledge, no conclusive guideline has been proposed on how to handle
11 missing cost and HRQoL data [36], and an exploration of methods for this should be
12 the subject of future work. A second minor limitation is associated with the possibility
13 of underestimating productivity losses, as we did not count productivity losses of
14 caregivers other than fathers or mothers (although non-parental caregivers were given
15 the option to complete the diaries; n=24, 9.4%). A more fundamental limitation is
16 related to the absence of standard methods for utility-yielding HRQoL elicitation for
17 young children. The choice of questions to collect health status information was based
18 on considering the available literature and options at the start of the study and extensive
19 deliberation between senior health economists and clinicians on the REspiratory
20 Syncytial virus Consortium in EUrope (RESCEU) project. The considerations towards
21 which these deliberations converged can be briefly summarised as follows. First,

1 quality of life measurement was not the primary aim of this cohort study (see also
2 Wildenbeest et al. [15]), and the questionnaire should not be too demanding on
3 respondents in order not to jeopardise the primary aims of the study. Second, the most
4 widely used and in many European country-specific guidelines for economic evaluation
5 recommended standard instrument, the EQ-5D, or a modified version thereof, has not
6 been validated for the HRQoL impact in children under the age of 4 years. Third,
7 changes on the health dimensions of “mobility”, “looking after myself” and “doing
8 usual activities” as standard in the EQ-5D can be considered irrelevant for infants and
9 could lead to irritation when repeatedly presented to respondents on a daily basis.
10 Fourth, the circumstances of recent parenthood, the associated emotional experience
11 and practical considerations would make a full parental EQ-5D assessment shortly after
12 they had a new baby difficult to interpret, vis-à-vis an age-adjusted population norm
13 (which may or may not contain an unknown prevalence of recent parents). Hence it
14 would be better to present the full EQ-5D-5L to caregivers one year after birth, despite
15 the health state can be affected by the long term sequelae of RSV. Fifth, the EQ-5D-
16 VAS is an intuitively attractive and rapid way to evaluate the evolving health status of
17 young children and their parents alike. Considering all these arguments, we only
18 included part of the EQ-5D questions to follow-up the infants’ health experience. In the
19 meantime, development and wider validation of a few promising preference-based
20 HRQoL instruments specifically for use in infants continues. Currently, the Infant
21 Quality of Life instrument (IQI) [37], which was validated for infants 1 month to 11

1 months of age, and the Toddler and Infant (TANDI) instrument [38], which was
2 validated for 1- to 36-month-old children seem good candidates for future utility
3 estimation. Another limitation was that the participants in this cohort might not be
4 representative of the respective country population. The labour force participation rate
5 of the caregivers in our sample (women/men, 89%/97%) was higher compared to that
6 in the respective countries (women/men, age group 35-39: 83%/94%, 83%/94%,
7 85%/94%, 81%/94% in Finland, the Netherlands, Spain, and the UK, respectively) in
8 2019 [39]. In addition, 70% of mothers in our cohort reported university education,
9 while the tertiary education attainment rates were 51%, 50.9%, 46.7%, 44.4% from 35
10 to 44 years in Finland, the UK, the Netherlands and Spain, respectively [40]. This could
11 have resulted in an underestimation of the cost burden and QALY loss, because
12 socioeconomic status was found to be associated with severe, early-life RSV-related
13 illness [41]. Finally, the advent of the SARS-CoV-2 pandemic after data collection was
14 finalised may have impacts we could not measure in our study.

15 **Conclusion**

16 This multi-country study is the first to prospectively collect RSV-associated costs and
17 HRQoL in RSV-infected healthy term infants and their families in a community setting.
18 It helps understand the current economic and health burden of RSV in infants younger
19 than one year of age, who are most likely to be affected by severe RSV infection. Our
20 estimates can be used to inform future decision-making regarding RSV-related
21 intervention programs for young children.

1 Given differences in healthcare systems and healthcare seeking behaviour, obtaining
2 country-specific RSV costs may be required. Efforts should continue to develop
3 standard tools to measure HRQoL in young children.

4 **RESCEU investigators**

5 Philippe Beutels (University of Antwerp); Louis Bont (University Medical Center
6 Utrecht); Federico Martinon-Torres (Servicio Galego de Saude), Terho Heikkinen
7 (University of Turku and Turku University Hospital); Andrew Pollard (University of
8 Oxford); Harish Nair and Harry Campbell (University of Edinburgh); Peter Openshaw
9 (Imperial College London); Adam Meijer (National Institute for Public Health and the
10 Environment); Thea K Fischer (Statens Serum Institut); Maarten van den Berge
11 (University of Groningen); Carlo Giaquinto (PENTA Foundation); Michael Abram
12 (AstraZeneca); Kena Swanson (Pfizer); Bishoy Rizkalla (GlaxoSmithKline); Charlotte
13 Vernhes and Scott Gallichan (Sanofi); Jeroen Aerssens (Janssen); Veena Kumar
14 (Novavax); Eva Molero (Team-IT Research)

15 **Ethics approval**

16 The study was approved by the Institutional Review Board (IRB) of the University
17 Medical Center Utrecht (Ref 17/069), NHS National Research Ethics Service
18 Oxfordshire Committee A (Ref 17/SC/0335) and South East Scotland Research Ethics
19 Committee (Ref 17/SS/0086), the Ethics Committee of the Hospital District of
20 Southwest Finland (Ref 17201), and Hospital Clínico Universitario de Santiago de
21 Compostela (Ref 2017/175).

1 **Author contribution**

2 The study was conceived and supervised by PB and LB, questionnaire-based data
3 collection was conceptualized by PB and JW in consultation with LB, BD and MP.
4 Cohort set up and implementation were done by LB, MNB, JW, KK, FMT, TH, SC,
5 MDS, HR, AJP. Unit cost data were collected by XL, ZM, AD and TH, statistical
6 analyses were conducted by ZM, in consultation with XL, JB, NH and PB. The first
7 draft of the manuscript was written by ZM. All authors critically reviewed the
8 manuscript and provided final approval of the manuscript.

9 **Acknowledgements**

10 We would like to thank Heini Salo for providing input data and advice for Finland. We
11 would also like to thank Mark Jit, Alexia Kieffer and You Li for their critical review
12 and valuable comments.

13 **Funding source**

14 Respiratory Syncytial Virus Consortium in Europe (RESCEU) has received funding
15 from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement
16 No 116019. This Joint Undertaking receives support from the European Union's
17 Horizon 2020 research and innovation programme and EFPIA.

18 The funder had no role in the study design, data collection, data analysis, data
19 interpretation, or writing of the report. The corresponding author had full access to all
20 the data in the study and had final responsibility for the decision to submit for
21 publication. This manuscript represents the views of the authors only. The European

1 Commission is not responsible for any use that may be made of the information it
2 contains.

3 **Conflict of interest**

4 PB reported consulting fees from Pfizer, GSK on 2 occasions for discussions on
5 economic evaluation, for a total of <€3000 combined, paid 100% directly to the
6 University of Antwerp. NH reported grants from Janssen Vaccines & Prevention BV
7 (R-11873) for collection of social contact data relevant for the spread of respiratory
8 pathogens including SARS-CoV-2, RSV, influenza. NH reports consulting fees from
9 Janssen Global Services for participation in advisory board related to RSV disease
10 transmission modelling; payments made to Hasselt University. LJB has regular
11 interaction with pharmaceutical and other industrial partners. He has not received
12 personal fees or other personal benefits. UMCU has received major funding (>€100,000
13 per industrial partner) for investigator initiated studies from AbbVie, MedImmune,
14 Janssen, the Bill and Melinda Gates Foundation, Nutricia (Danone) and MeMed
15 Diagnostics. UMCU has received major cash or in kind funding as part of the public
16 private partnership IMI-funded RESCEU project from GSK, Novavax, Janssen,
17 AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical
18 for participating in the INFORM study sponsored by MedImmune. UMCU has received
19 minor funding for participation in trials by Regeneron and Janssen from 2015-2017
20 (total annual estimate less than €20,000). UMCU received minor funding for
21 consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic,

1 MabXience, Novavax, Pfizer, Janssen (total annual estimate less than €20,000). Dr.
2 Bont is the founding chairman of the ReSViNET Foundation. SC reported IMI –
3 RESCEU grant funding (as detailed in manuscript), with fees paid to the University of
4 Edinburgh. FM-T has received honoraria from GSK group of companies, Pfizer Inc,
5 Sanofi Pasteur, MSD, Seqirus, Biofabri and Janssen for taking part in advisory boards
6 and expert meetings and for acting as a speaker in congresses outside the scope of the
7 submitted work. FM-T has also acted as principal investigator in randomized controlled
8 trials of the above-mentioned companies as well as Ablynx, Gilead, Regeneron, Roche,
9 Abbott, Novavax, and MedImmune, with honoraria paid to his institution. SBD had
10 received honoraria from MSD and Sanofi Pasteur for taking part in advisory boards and
11 has provided consultancy and/or investigator roles in relation to product development
12 for Janssen, AstraZeneca, Pfizer, Valneva, MSD and Sanofi Pasteur with fees paid to St
13 George's University of London. TH has received honoraria for lectures and/or
14 participation in advisory boards or data monitoring committees from Janssen, Sanofi
15 Pasteur, Enanta and MSD. MDS acted until September 2022 on behalf of the University
16 of Oxford as an Investigator on research studies funded or supported by the vaccine
17 manufacturers GlaxoSmithKline, Janssen, AstraZeneca, Novavax, MCM vaccines and
18 Pfizer. He received no direct personal benefit for this work. From September 2022 he
19 has been an employee at Moderna Biotech UK and holds stock options in this company.
20 AJP is a member of AMS and Senior Investigator of NIHR. KK has received fees for
21 interview for expert opinion considering the burden of RSV in older adults with IQVIA

(part of Janssen) as well as interview for expert opinion considering the burden of RSV in older adults with Deallus. AD has participated as sub-investigator in clinical trials and observational studies for Novavax, MedImmune, Janssen GSK, Pfizer, Merk, Sharp Donme, ReViral, Enanta Pharmaceuticals. All payments were made to the institution and no direct payment was received. MJP is a member of JCVI and reports stock or stock options for HealthEcore (25% of shares) and PAG BV (100% of shares). All other authors report no potential conflicts of interest.

References:

1. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *The Lancet* **2022**; 399:2047-64.
2. Toivonen L, Karppinen S, Schuez-Havupalo L, et al. Respiratory syncytial virus infections in children 0–24 months of age in the community. *J Infect* **2020**; 80:69-75.
3. Thomas E, Mattila J-M, Lehtinen P, Vuorinen T, Waris M, Heikkinen T. Burden of respiratory syncytial virus infection during the first year of life. *J Infect Dis* **2021**; 223:811-7.
4. Hammit LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. *N Engl J Med* **2022**; 386:837-46.
5. Madhi SA, Polack FP, Piedra PA, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. *N Engl J Med* **2020**; 383:426-39.
6. Zhang S, Akmar LZ, Bailey F, et al. Cost of respiratory syncytial virus-associated acute lower respiratory infection management in young children at the regional and global level: a systematic review and meta-analysis. *J Infect Dis* **2020**; 222:S680-S7.
7. Garcia-Marcos L, Valverde-Molina J, Pavlovic-Nesic S, et al. Pediatricians' attitudes and costs of bronchiolitis in the emergency department: A prospective multicentre study. *Pediatr Pulmonol* **2014**; 49:1011-9.
8. Drysdale SB, Alcazar-Paris M, Wilson T, et al. Rhinovirus infection and healthcare utilisation in prematurely born infants. *Eur Respir J* **2013**; 42:1029-36.
9. Ehlken B, Ihorst G, Lippert B, et al. Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany. *Eur J Pediatr* **2005**; 164:607-15.
10. Meijboom M, Rozenbaum M, Benedictus A, et al. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands. *Vaccine* **2012**; 30:4691-700.

11. Régnier SA. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine. *Vaccine* **2013**; 31:4347-54.
12. Pouwels KB, Bozdemir SE, Yegenoglu S, et al. Potential cost-effectiveness of RSV vaccination of infants and pregnant women in Turkey: an illustration based on bursa data. *PloS one* **2016**; 11:e0163567.
13. Díez-Gandía E, Gómez-Álvarez C, López-Lacort M, et al. The impact of childhood RSV infection on children's and parents' quality of life: a prospective multicenter study in Spain. *BMC Infect Dis* **2021**; 21:1-9.
14. Hodgson D, Atkins KE, Baguelin M, et al. Estimates for quality of life loss due to Respiratory Syncytial Virus. *Influenza Other Respir Viruses* **2020**; 14:19-27.
15. Wildenbeest JG, Zuurbier RP, Korsten K, et al. Respiratory Syncytial Virus Consortium in Europe (RESCEU) birth cohort study: defining the burden of infant respiratory syncytial virus disease in Europe. *J Infect Dis* **2020**; 222:S606-S12.
16. Wildenbeest JG, Billard M-N, Zuurbier RP, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. *Lancet Respiratory Medicine* **2022**.
17. National Health Service. National Schedule of NHS costs - Year 2019-20 - NHS trust and NHS foundation trusts. Available at: <https://www.england.nhs.uk/publication/2019-20-national-cost-collection-data-publication/>. Accessed 11 May 2022.
18. Institute for Medical Technology Assessment Erasmus Universiteit Rotterdam. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Available at: <https://www.zorginstituutnederland.nl>. Accessed 10 November 2021.
19. Mäklin S, Kokko P. Terveystien ja sosiaalihuollon yksikkökustannukset Suomessa vuonna 2017. Työpaperi 21/2020. Helsinki: Terveystien ja hyvinvoinnin laitos. Available at: <https://www.julkari.fi/handle/10024/142882>. Accessed 3 March 2022.
20. Diario Oficial de Galicia. DECRETO 56/2014, do 30 de abril, polo que se establecen as tarifas dos servizos sanitarios prestados nos centros dependentes do Servizo Galego de Saúde e nas fundacións públicas sanitarias. Available at: https://www.xunta.gal/dog/Publicados/2014/20140521/AnuncioC3K1-140514-0001_es.html. Accessed 22 March 2022.
21. EuroQol Research Foundation. EQ-5D User Guides. Available at: <https://euroqol.org/publications/user-guides>. Accessed 1 June 2022.
22. Versteegh MM, Vermeulen KM, Evers SM, De Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. *Value health* **2016**; 19:343-52.
23. Ramos-Goñi JM, Craig BM, Oppe M, et al. Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach. *Value Health* **2018**; 21:596-604.
24. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health - related quality of life: An EQ - 5D - 5L value set for England. *Health Econ* **2018**; 27:7-22.
25. Jensen CE, Sørensen SS, Gudex C, Jensen MB, Pedersen KM, Ehlers LH. The Danish EQ-5D-5L value set: a hybrid model using cTTO and DCE data. *Appl Health Econ Health Policy* **2021**; 19:579-91.
26. Ramos-Goñi JM, Oppe M, Estévez-Carrillo A, et al. Accounting for unobservable preference heterogeneity and evaluating alternative anchoring approaches to estimate country-specific EQ-5D-Y value sets: a case study using Spanish preference data. *Value Health* **2022**; 25:835-43.
27. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, **2013**.

28. Heikkinen T, Ojala E, Waris M. Clinical and socioeconomic burden of respiratory syncytial virus infection in children. *J Infect Dis* **2017**; 215:17–23.
29. Wittenberg E, Prosser LA. Disutility of illness for caregivers and families: a systematic review of the literature. *Pharmacoeconomics* **2013**; 31:489-500.
30. Kela. Maternity, paternity and parental allowances. Available at: <https://www.kela.fi/parental-allowances>. Accessed Jan 10 2023.
31. Heshmati A, Honkaniemi H, Juárez SP. The effect of parental leave on parents' mental health: a systematic review. *Lancet Public Health* **2023**; 8:e57-e75.
32. Noyes J, Edwards R. EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. *Value Health* **2011**; 14:1117-29.
33. Roy L, Bansback N, Marra C, Carr R, Chilvers M, Lynd LD. Evaluating preferences for long term wheeze following RSV infection using TTO and best-worst scaling. In: *Allergy Asthma Clin Immunol*. Springer:A64.
34. Verstraete J, Ramma L, Jelsma J. Influence of the child's perceived general health on the primary caregiver's health status. *Health Qual Life Outcomes* **2018**; 16:1-11.
35. Verstraete J, Scott D. Does the child's health influence the caregiver's health using the EQ-5D instruments? *S Afr J Physiother* **2020**; 76:a1343.
36. Rösel I, Serna-Higuera LM, Al Sayah F, et al. What difference does multiple imputation make in longitudinal modeling of EQ-5D-5L data? Empirical analyses of simulated and observed missing data patterns. *Qual Life Res* **2022**; 31:1521-32.
37. Krabbe PF, Jabrayilov R, Detzel P, Dainelli L, Vermeulen KM, van Asselt AD. A two-step procedure to generate utilities for the Infant health-related Quality of life Instrument (IQI). *PloS one* **2020**; 15:e0230852.
38. Verstraete J, Ramma L, Jelsma J. Validity and reliability testing of the Toddler and Infant (TANDI) Health Related Quality of Life instrument for very young children. *J Patient-Rep Outcomes* **2020**; 4:94.
39. OECD. LFS by sex and age - indicators. Available at: https://stats.oecd.org/Index.aspx?DataSetCode=lfs_sexage_i_r#. Accessed 24 Jan 2023.
40. Eurostat. Population by educational attainment level, sex and age (%). Available at: https://ec.europa.eu/eurostat/databrowser/view/EDAT_LFSE_03_custom_4636020/default/table?lang=en. Accessed 24 Jan 2023.
41. Fitzpatrick T, McNally J, Stukel TA, et al. Family and child risk factors for early-life RSV illness. *Pediatrics* **2021**; 147.

1 **Tables:**

2 Table 1: Baseline characteristics of RSV episodes (N=265)

	RSV episodes (N=265)
Study site	
Spain	62 (23.4%)
Finland	21 (7.9%)
The UK	95 (35.9%)
The Netherlands	87 (32.8%)
Season	
2017-18	18 (6.8%)
2018-19	81 (30.6%)
2019-20	166 (62.6%)
Gender of infants	
Female	124 (46.8%)
Male	140 (52.8%)
Missing	1 (0.4%)
Mother Education	
Primary	3 (1.1%)
Secondary	16 (6.0%)
Vocational	57 (21.5%)
Applied University	82 (30.9%)
Science University	107 (40.4%)
Father Education	
Primary	7 (2.6%)
Secondary	30 (11.3%)
Vocational	70 (26.4%)
University of applied sciences*	66 (24.9%)
University of sciences	90 (34.0%)
Missing	2 (0.8%)
Mother work status (before the birth of the newborn)	
Full-time	152 (57.4%)
Part-time	83 (31.3%)
Full-time caring for the children	6 (2.3%)
No	15 (5.7%)
Other	9 (3.4%)
Mother work status (resume working after the maternity leave)	
Yes, full-time	82 (30.9%)
Yes, part-time	125 (47.2%)
No	11 (4.2%)
Unknown	47 (17.7%)
Father work status (before the birth of the newborn)	
Full-time	236 (89.1%)
Part-time	20 (7.5%)
Full-time caring for the children	0 (0)
No	5 (1.9%)
Other	4 (1.5%)
Father work status (resume working after the paternity leave)	
Yes, full-time	221 (83.4%)
Yes, part-time	31 (11.7%)
No	1 (0.4%)
Unknown	12 (4.5%)
Other characteristics	
ARTI age (in months): Mean [median] (IQR)	6.0 [5.8] (3.7-8.5)
Mother age: Mean [median] (IQR)	33.8 [34] (31-36)
Father age: Mean [median] (IQR)	36.0 [36] (33-39)

% Maternal influenza vaccination	108 (40.8%)
% Maternal pertussis	150 (56.6%)
% Smoke during pregnancy	11 (4.2%)
% Smoke in the household	32 (12.1%)

1 * Universities of applied sciences are mostly practical and profession-orientated; universities of science are academical orientated.

2

1 Table 2: Average costs per RSV episode

	Healthcare payer		Societal		
	Mean (95% CI) *	Median (Q1-Q3)	Mean (95% CI)	Median (Q1-Q3)	Number
Pooled	399.5 (242.3, 584.2)	26.9 (0-85)	494.3 (317.7, 696.1)	40.6 (1.3-290.2)	256
AMB vs Hospital vs Non-MA					
AMB	167.8 (129.9, 202.9)	73 (41.2-222)	254.7 (197.9, 318.2)	87.2 (44.2-383.3)	116
Hospital	4587.9 (3085, 6229)	3479.7 (2591.8-5548.2)	5094.9 (3507, 6894)	3785.8 (2655.5-6636.7)	18
Non-MA	1.8 (1.4, 2.3)	0 (0-2.5)	44.2 (17.13, 80.98)	0.9 (0-4.3)	120
Different countries					
Finland	317.7 (103.1, 692.7)	89.3 (2.1-301.7)	395.1 (145.5, 777.6)	182.9 (2.12-303.8)	21
Netherlands	335.4 (116.8, 660.3)	7.9 (0-44.4)	445.5 (197.7, 801.6)	40.6 (0-211.3)	86
Spain	803.7 (322.2, 1460.4)	75.1 (1.8-466.3)	912.9 (383.4, 1588.1)	75.1 (1.75-471.3)	61
UK	201.4 (66.7, 383.1)	7.4 (2.5-46.2)	275.6 (115.3, 482.3)	11.4 (2.5-48.3)	88

2 * Confidence intervals were calculated by using bootstrapping (1000 bootstrap samples). Abbreviations: AMB, ambulatory care;

3 Non-MA: non-medical attendance; CI, confidence interval.

4

1 Table 3: Average QALD loss of infants and caregivers per RSV episode

		QALD loss		Number
		Mean (95% CI)	Median (Q1-Q3)	
Infant	Infant pooled	1.9 (1.7, 2.1)	1.7 (0.8 – 2.7)	180
By healthcare resource use*	AMB	2.3 (2.0, 2.6)	2.1 (1.4 – 2.9)	81
	Non-MA	1.3 (1.1, 1.6)	1.1 (0.5 – 1.9)	90
	Hospitalised	3.7 (3.3, 4.3)	3.6 (3.3 – 4.1)	7
By country	Spain	2.3 (1.9, 2.7)	2.3 (1.4 – 3.1)	36
	Finland	2.0 (1.5, 2.6)	1.7 (1.4 – 2.6)	14
	UK	1.8 (1.5, 2.1)	1.7 (0.9 – 2.5)	76
	Netherlands	1.6 (1.2, 2.0)	1.1 (0.5 – 2.6)	54
By caregiver	All-mother	1.9 (1.6, 2.1)	1.7 (0.8 – 2.7)	146
	All-father	2.0 (1.4, 2.6)	2.3 (1.1 – 2.7)	8
Caregivers	Caregivers pooled	0.1 (0, 0.2)	0.1 (0 – 0.4)	164
By healthcare resource use	AMB	0.2 (0, 0.4)	0.2 (0 – 0.5)	75
	Non-MA	-0.1 (-0.3, 0.1)	0 (-0.1 - 0.2)	81
	Hospitalised	1.2 (0.8, 1.7)	0.9 (0.9 – 1.6)	6
By country	Spain	0.2 (0, 0.3)	0 (0 – 0.3)	33
	Finland	-0.5 (-1.2, 0.1)	0 (-0.7 – 0.1)	14
	UK	0.2 (0.1, 0.4)	0.1 (-0.1 – 0.5)	69
	Netherlands	0 (-0.2, 0.2)	0 (0 – 0.3)	48
By caregiver	All-mother	0.1 (-0.1, 0.2)	0 (0 – 0.4)	133
	All-father	0.1 (-0.2, 0.4)	0 (0 – 0.2)	8

2 * Two episodes did not have healthcare resource use status. Abbreviations: QALD, quality-adjusted life-day; AMB, ambulatory
3 care; non-MA, non-medical attendance; CI, confidence interval; Q1, first interquartile; Q3: third interquartile.


4

5

1 **Figures**

2

3 Figure 1: Patient flowchart for cost and health-related quality-of-life analysis




4

5 Abbreviations: ARTI, acute respiratory tract infection; RSV, respiratory syncytial virus; HRQoL, health-related quality of life.

6

1


2 Figure 2: Proportions of participants having any problem in 5 health dimensions (2 for
3 children and 3 for caregivers)



4

5

1 Figure 3: Boxplots of EQ-Visual Analogue Scale (VAS) scores for infants with RSV
 2 and caregivers



3

4